Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.

Journal of Pain and Symptom Management
S Gail EckhardtRoland Bugat

Abstract

In this randomized, double-blind, placebo-controlled study comparing gemcitabine+tipifarnib (G+t) or gemcitabine+placebo (G+p) in patients with pancreatic cancer, the primary endpoint of time to deterioration (TTD) was based primarily on patient-reported outcomes. Deterioration was defined as death or worsening of disease-related symptoms, based on patient-reported outcomes of pain intensity and analgesic use in a daily diary, plus investigator-rated weekly performance status. Secondary endpoints included survival and safety. Two hundred and forty-four patients were treated for a total of 4780 weeks, during which the diary was completed daily. Overall, the completion of the diary was found to be feasible: patients completed approximately 95% of scheduled diary entries. Baseline characteristics were well balanced between the two treatment arms. The primary endpoint of TTD was not significantly different between the G+t arm (69 days) and the G+p arm (91 days, P=0.40). Survival was not significantly different between the G+t arm (202 days) and the G+p arm (221 days, P=0.66). The combination of G+t had an acceptable toxicity profile, with primarily neutropenia and thrombocytopenia. Methodologically, measurement of patient-reported ...Continue Reading

References

Jul 11, 1985·The New England Journal of Medicine·K M Foley
Mar 1, 1994·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·W Korte, R Morant
Apr 17, 2003·The Oncologist·Sarah McKenna, Martin Eatock
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen R D JohnstonAngela Howes
Dec 5, 2003·Alimentary Pharmacology & Therapeutics·S ShoreJ P Neoptolemos
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Van CutsemD Von Hoff
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group

❮ Previous
Next ❯

Citations

Sep 25, 2012·World Journal of Gastroenterology : WJG·Chen SunDe-Quan Wu
Nov 19, 2013·Journal of Comparative Effectiveness Research·Boris FreidlinEdward L Korn
Aug 19, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Lin ChenShuchun Luo
Feb 8, 2016·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Domenico CilibertoPierosandro Tagliaferri
Jan 29, 2016·Critical Reviews in Oncology/hematology·A KristensenT S Solheim
Jul 3, 2010·Drug Discovery Today·Lisanne L KrensHenk-Jan Guchelaar
Sep 8, 2016·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·M M VickersD Goldstein
Jun 13, 2018·Advanced Materials·Ali K YetisenHaider Butt
Aug 6, 2019·Cancer·Gordon T MoffatEileen M O'Reilly
Jan 27, 2010·Current Opinion in Supportive and Palliative Care

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
A RussoN Gebbia
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Shirin Khambata-FordDavid J Mauro
© 2022 Meta ULC. All rights reserved